GH Research (GHRS) Capital Expenditures (2021 - 2025)
GH Research (GHRS) recorded quarterly Capital Expenditures of -$19000.0 in Q4 2025, up 51.28% quarter-over-quarter from -$39000.0 in Q3 2025, and up 24.0% on a YoY basis from -$15322.6 in Q4 2024.
GH Research (GHRS) Capital Expenditures (2021 - 2025) Analysis & Trends
GH Research's Capital Expenditures history runs 5 years deep, the most recent figure standing at -$19000.0 for Q4 2025.
- In Q4 2025, Capital Expenditures rose 24.0% year-over-year to -$19000.0; the TTM figure through Dec 2025 stood at -$121000.0 (down 146.94% YoY), while the FY2025 annual figure was -$121000.0, down 146.94% from the prior year.
- Capital Expenditures was -$19000.0 for Q4 2025 at GH Research, up from -$39000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $189000.0 in Q4 2021 to a low of -$59000.0 in Q2 2025.
- Historically, Capital Expenditures has averaged $5050.0 across 5 years, with a median of -$14500.0 in 2021.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures jumped 82.61% in 2024, then tumbled 875.0% in 2025.
- A 5-year view of Capital Expenditures shows it stood at $189000.0 in 2021, then tumbled by 38.62% to $116000.0 in 2022, then soared by 51.72% to $176000.0 in 2023, then tumbled by 114.2% to -$25000.0 in 2024, then increased by 24.0% to -$19000.0 in 2025.
- The last three Capital Expenditures figures came in at -$19000.0 (Q4 2025), -$39000.0 (Q3 2025), and -$59000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -63,220.27 |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - | -19,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -19,000.00 |
| Dec 31, 2025 | -19,000.00 |
| Sep 30, 2025 | -39,000.00 |
| Sep 30, 2025 | -39,000.00 |
| Jun 30, 2025 | -59,000.00 |
| Jun 30, 2025 | -59,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Sep 30, 2024 | -4,000.00 |
| Sep 30, 2024 | -4,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | -12,000.00 |
| Mar 31, 2024 | -12,000.00 |
| Dec 31, 2023 | 176,000.00 |
| Dec 31, 2023 | 176,000.00 |
| Sep 30, 2023 | -8,000.00 |
| Sep 30, 2023 | -8,000.00 |